Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Elisavet Papadimitraki"'
Autor:
Aristea Kalikaki, Helen Politaki, John Souglakos, Stella Apostolaki, Elisavet Papadimitraki, Nefeli Georgoulia, Maria Tzardi, Dimitris Mavroudis, Vassilis Georgoulias, Alexandra Voutsina
Publikováno v:
PLoS ONE, Vol 9, Iss 8, p e104902 (2014)
Circulating tumor cells (CTCs) could represent a non-invasive source of cancer cells used for longitudinal monitoring of the tumoral mutation status throughout the course of the disease. The aims of the present study were to investigate the detection
Externí odkaz:
https://doaj.org/article/2d96b3b05de14b82abdce8a3dd4a2329
Autor:
Sophia Agelaki, I. Bompolaki, E. Kontopodis, Vassilis Chandrinos, Elisavet Papadimitraki, Ζ. Zafeiriou, Athanasios Kotsakis, Kostas Kalbakis, D. Stoltidis, V. Georgoulias
Publikováno v:
Cancer Chemotherapy and Pharmacology. 72:45-51
To determine the dose-limiting toxicities (DLTs) and the maximum tolerated dose (MTD) of oral topotecan administered weekly in patients with relapsed small cell lung cancer (SCLC). Patients were treated with oral topotecan on days 1, 8, and 15, every
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47e69a414306cf8ff61b12aaf6c8c346
https://doi.org/10.1007/s00280-013-2167-0
https://doi.org/10.1007/s00280-013-2167-0
Autor:
Vasiliki Bozionelou, D. Mavroudis, Kostas N. Syrigos, N. Karachaliou, V. Georgoulias, Elisavet Papadimitraki, Antonia Kalykaki, E. Kontopodis, Nikolaos Ziras, K. Tryfonidis
Publikováno v:
Cancer Chemotherapy and Pharmacology. 70:169-176
To evaluate the docetaxel–gemcitabine (DG) combination administered every 2 weeks as salvage therapy in anthracycline- and taxane-pretreated patients with metastatic breast cancer (MBC). Thirty women with MBC who had disease progression after chemo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3487efab7bce21594a893530517d9308
https://doi.org/10.1007/s00280-012-1901-3
https://doi.org/10.1007/s00280-012-1901-3
Autor:
Stylianos Giassas, V. Georgoulias, N. Vardakis, V. Bozionellou, Nikolaos Kentepozidis, A. Kotsakis, Elisavet Papadimitraki, A. Soultati, Antonia Kalykaki, N. Pantazopoulos
Publikováno v:
Cancer Chemotherapy and Pharmacology. 70:161-168
To evaluate the efficacy and tolerance of biweekly paclitaxel and carboplatin combination in patients with castration-resistant prostate cancer.Patients were treated with paclitaxel at the dose of 135 mg/m(2) followed by carboplatin AUC 3 on day 1 ev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48a202cae99753c7a682f6388a70f38f
https://doi.org/10.1007/s00280-012-1896-9
https://doi.org/10.1007/s00280-012-1896-9
Autor:
Soultana Christou, Athanasios Kotsakis, Stefania Patramani, G. Konsolakis, Despoina Aggouraki, Vassilis Georgoulias, Marina-Eleni Mela, C. Christophyllakis, Dimitris Mavroudis, Marina Alefantinou, Ageliki Kaskara, Kostas Kosmatopoulos, Eleni-Kyriaki Vetsika, Elisavet Papadimitraki
Publikováno v:
Journal of Immunotherapy. 34:641-650
The aim of this study was to investigate the best administration of telomerase reverse transcriptase (TERT572), an human leukocyte antigen-A*0201-restricted cryptic epitope of telomerase, and its optimized variant TERT(572Y) to elicit specific T cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eab16914ce8733e4c85637fb5f103ba2
https://doi.org/10.1097/cji.0b013e31823284a6
https://doi.org/10.1097/cji.0b013e31823284a6
Autor:
Eugenios Daphnis, Konstantinos Giannakakis, Vasilios Georgoulias, Christina Liotsi, Nikos Kroustalakis, Eirini Lioudaki, Kostas Stylianou, Elisavet Papadimitraki, George Kokologiannakis
Publikováno v:
Nephrology Dialysis Transplantation. 26:1742-1745
Bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, has been widely used in a variety of malignancies offering substantial clinical benefit. Hypertension and proteinuria are the most commonly reported manifestations of bevacizumab-rel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6bd42cdbc8cd08d69925893dcb64957
https://doi.org/10.1093/ndt/gfr093
https://doi.org/10.1093/ndt/gfr093
Autor:
Maria Stathaki, Elisavet Papadimitraki, Lampros Vamvakas, Nikolaos Karkavitsas, Angeliki Tsaroucha, Emmanouela Papadaki
Publikováno v:
Clinical Nuclear Medicine. 37:1112-1114
A 70-year-old man with a history of weight loss, changes in bowel habits, and hematochezia had rectal adenocarcinoma. He was palliated with diverting colostomy, followed by radiochemotherapy. Bilateral hydronephrosis was found incidentally on lower a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53762153ff9cf49d219e7f1b4222fe4d
https://doi.org/10.1097/rlu.0b013e31826c0d27
https://doi.org/10.1097/rlu.0b013e31826c0d27
Autor:
Christos Emmanouilidis, Zafeiris Zafeiriou, Antonia Kalykaki, Vassilis Georgoulias, Kostas Kalbakis, Elisavet Papadimitraki, Filippos Koinis, Aristidis Polyzos, George Samonis, Athina Christopoulou
Publikováno v:
Cancer chemotherapy and pharmacology. 73(4)
To evaluate the safety and antitumor activity of docetaxel (DOC) and pegylated liposomal doxorubicin (PLD) combination in patients with platinum- and taxane-sensitive ovarian cancer.Twenty-three patients were enrolled. DOC was administered at the dos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fd7d65e2d5526f36e3406d012c78101
https://pubmed.ncbi.nlm.nih.gov/24531559
https://pubmed.ncbi.nlm.nih.gov/24531559
Autor:
Athanasios Kotsakis, Eleni-Kyriaki Vetsika, Vassilis Georgoulias, Despoina Aggouraki, Nikolaos Kentepozidis, Elisavet Papadimitraki, Eleftheria Kleio Dermitzaki, Dimitris Mavroudis, Dora Hatzidaki
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 86(1)
The immunological and clinical responses of patients with NSCLC treated, in the context of an expanded action program, with the cryptic hTERT-targeting Vx-001 vaccine are presented.Forty-six HLA-A*0201-positive patients with advanced NSCLC and residu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e929bde595226a5534ae250112d5ac11
https://pubmed.ncbi.nlm.nih.gov/25130084
https://pubmed.ncbi.nlm.nih.gov/25130084
Autor:
Giorgia Zucchini, Eirini Thanopoulou, D. Okonji, Laura M. Kenny, Panagiotis Papanastasopoulos, Martin S. Hogg, Komel Khabra, Jaseela Chiramel, Stephen R. D. Johnston, Andrew M Wardley, Sacha J Howell, Elisavet Papadimitraki, S. Redana, Alistair Ring
Publikováno v:
Journal of Clinical Oncology. 34:576-576
576Background: EXE-EVE significantly improved progression free survival (PFS) in patients (pts) with HR+ MBC progressing on a nonsteroidal aromatase inhibitor regardless of age, at the expenses of ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dc06585c007286f1af2a12c5c45ede78
https://doi.org/10.1200/jco.2016.34.15_suppl.576
https://doi.org/10.1200/jco.2016.34.15_suppl.576